TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3706879
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate (AS) 6.4 mg total (3.2 mg inhaled twice)
Study: 3706879
Drug: Metaproterenol sulfate
Normalized name: Metaproterenol Sulfate
DrugBank: Orciprenaline (DB00816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metaproterenol sulfate (MP) 30 mg total (15 mg inhaled twice)
Study: 30928806
Drug: Eribulin (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin (1.4 mg/m2, intravenously, on day 1 and day 8)
Study: 30928806
Drug: Vinorelbine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine (25 mg/m2, intravenously, on day 1, day 8 and day 15)
Study: 22084195
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of 150 × 10(6) autologous bone marrow mononuclear cells (BMCs)
Study: 22084195
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of 150 × 10(6) autologous BMCs
Study: 19407945
Drug: Intravenous dripping
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dripping of Qingkailing Injection in combination with oral intake of Er'tong Qingfei Oral Liquid
Study: 19407945
Drug: Intravenous dripping
Normalized name: DRIP COLLECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dripping of ribavirin injection in combination with oral intake of potassium guaiacol sulfonate oral liquid
Study: 10736973
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg/day in 4 divided doses for 3 days)
Study: 10736973
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg/day in 4 divided doses for 3 days) plus Pyridostigmine (120 mg p.o.)
Study: 10736973
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg/day in 4 divided doses for 3 days) plus MCP (2.5 mg in an i.v. bolus injection)
Study: 10736973
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg/day in 4 divided doses for 3 days) plus Pyridostigmine (120 mg p.o.) plus MCP (2.5 mg in an i.v. bolus injection)
Study: 1353742
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml HiEPA fish oil (4.5 g of eicosapentaenoic acid) daily for one year
Study: 1353742
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil placebo daily for one year
Study: 1353742
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml HiEPA fish oil
Study: 6233921
Drug: Hepatitis B
Normalized name: HEPATITIS B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis B vaccine (20 micrograms, three doses)
Study: 20602892
Drug: Micronutrients supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrients supplement
Study: 18614731
Drug: Methionine intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine intake ranging from 10 to 120 mg x kg(‐1) x d(‐1)
Study: 16372879
Drug: Breast cancer
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast cancer vaccines
Study: 16372879
Drug: Standard breast
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard breast cancer drugs or novel immunotherapeutics
Study: 6306094
Drug: Ranitidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine and antacids
Study: 25115438
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of 2000 IU of vitamin D3 per day
Study: 25115438
Drug: Monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dosing of 40,000 IU of vitamin D3 per month
Study: 22289281
Drug: Phenylephrine (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (0.01 μg/kg/min)
Study: 22289281
Drug: Control (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (conventional anesthetic drugs and 20 ml/kg of lactated Ringer's over 30 mins)
Study: 17254365
Drug: Single session
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session of behavioural treatment (n=16)
Study: 15008926
Drug: Early loading
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early loading of ITI implants (2 weeks after placement)
Study: 8448097
Drug: Low Volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Volume (LV) group: 1.5 to 2 mL per hour of bupivacaine 0.5% with sufentanil 4 micrograms/mL
Study: 8448097
Drug: High Volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Volume (HV) group: 6 to 8 mL per hour of bupivacaine 0.125% with sufentanil 1 microgram/mL
Study: 2427843
Drug: Celiprolol 600
Normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol 600 mg once daily
Study: 23294052
Drug: OFC (olanzapine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFC (olanzapine + fluoxetine)
Study: 21464252
Drug: Intravenous peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous peramivir 300 mg/day
Study: 21464252
Drug: Intravenous peramivir
Normalized name: Peramivir
DrugBank: Peramivir (DB06614)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous peramivir 600 mg/day
Study: 17998674
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (Cisplatin 80 mg/m2 on day 1 and Etoposide 100 mg/m2 on days 1-3, q3 weeks for 3 cycles) followed by radiotherapy (6000 cGy/30 fractions) and 3 more cycles of the same chemotherapy regimen
Study: 17998674
Drug: Radiotherapy (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy (5000 cGy/25 fractions) with concurrent chemotherapy (cisplatin 20 mg/m2 + Etoposide 75 mg/m2 on days 1-5 and days 22-26), followed by 2 more cycles of chemotherapy, q3 weeks with the same regimen
Study: 12737444
Drug: Oral budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral budesonide (3 mg three times daily for 8 days)
Study: 7967322
Drug: Isosorbide dinitrate,
Normalized name: isosorbide dinitrate, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide dinitrate, 10 mg (ID)
Study: 7967322
Drug: Nifedipine, 20
Normalized name: Nifedipine, 20 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine, 20 mg (N)
Study: 7967322
Drug: Propranolol, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 40 mg (P)
Study: 7967322
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ID, 10 mg + P, 40 mg
Study: 7967322
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of N, 20 mg + P, 40 mg
Study: 7967322
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ID, 10 mg + N, 20 mg
Study: 3514491
Drug: Dihydroergotamine (time-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroergotamine (time-release preparation)
Study: 31242300
Drug: fIPV, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: fIPV, 0.1 mL im
Study: 31242300
Drug: fIPV, 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: fIPV, 0.2 mL im
Study: 31242300
Drug: fIPV, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: fIPV, 0.1 mL id
Study: 31242300
Drug: IPV, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPV, 0.5 mL im
Study: 23709329
Drug: 23-G microincision
Normalized name: calcium gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 23-G microincision vitrectomy surgery (MIVS)
Study: 23709329
Drug: 25-G microincision
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25-G microincision vitrectomy surgery (MIVS)
Study: 23709329
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 23-G and 25-G MIVS
Study: 18678294
Drug: Combined aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined aspirin 100 mg/day plus clopidogrel 75 mg/day
Study: 9493476
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 to 200 mg/day for 10 to 20 days)
Study: 8177920
Drug: Nimodipine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (active drug)
Study: 31599955
Drug: Nutrient-enriched donor
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nutrient-enriched donor milk (≥120 mL·kg‐1·d‐1)
Study: 29914380
Drug: VASP-guided clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: VASP-guided clopidogrel maintenance therapy titrated by platelet reactivity index (PRI)
Study: 29914380
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with fixed clopidogrel maintenance dose of 75 mg per day
Study: 29914380
Drug: VASP-guided clopidogrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: VASP-guided clopidogrel maintenance therapy
Study: 28366170
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of ciprofloxacin 500 mg orally twice daily
Study: 28366170
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of ciprofloxacin 500 mg orally twice daily
Study: 24189336
Drug: Combination gait
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination gait training (robot-assisted treadmill training followed by conventional body-weight-supported treadmill training)
Study: 16800988
Drug: Glucuronolactone tablets
Normalized name: glucuronolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucuronolactone tablets and inosine injection (Control)
Study: 14665354
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of oral rofecoxib
Study: 9084325
Drug: 10% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% CHX gel in gel trays on two consecutive days, followed by application of a fluoride varnish (Group A)
Study: 9084325
Drug: 10% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% CHX gel (Group B)
Study: 7104176
Drug: Triamterene 100
Normalized name: triamterene 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene 100 mg daily
Study: 7104176
Drug: Triamterene 200
Normalized name: Triamterene
DrugBank: Triamterene (DB00384)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamterene 200 mg daily
Study: 7104176
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride 32 mmol daily
Study: 7104176
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride 64 mmol daily
Study: 27940287
Drug: Glycopyrronium 44
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrronium 44 μg
Study: 25501868
Drug: Apixaban 50
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 50 mg QD for 3 days
Study: 25501868
Drug: Apixaban 10
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg QD for 3 days
Study: 25501868
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg on Day 3
Study: 24493300
Drug: Clonidine hydrochloride
Normalized name: Clonidine Hydrochloride
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine hydrochloride (25 µg or 50 µg twice daily for 9 weeks)
Study: 24493300
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 9 weeks
Study: 22806348
Drug: Glucose-lowering drugs
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-lowering drugs (non-insulin)
Study: 19241310
Drug: Fluvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (80 mg/day, n = 23)
Study: 17335328
Drug: Nefazodone (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (300-600 mg/day, flexible dose)
Study: 7561468
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no nasal medication)
Study: 26559255
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid 0.4 mg/day (low-FA)
Study: 26559255
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid 0.8 mg/day (high-FA)
Study: 25236946
Drug: Hypobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric bupivacaine 3.75 mg (B0.25 group)
Study: 25236946
Drug: Hypobaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypobaric bupivacaine 7.5 mg (B0.5 group)
Study: 22114872
Drug: Quercetin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (500 mg capsules, once daily for 14 days)
Study: 12081581
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.6 g/kg/day)
Study: 12081581
Drug: Usual-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-protein diet (1.02 g/kg/day)
Study: 31382835
Drug: Lutein water-soluble
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein water-soluble formulation
Study: 31382835
Drug: Lutein oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein oil suspension
Study: 28755807
Drug: Cholesterol lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol lowering treatment (simvastatin 40 mg/day, ezetimibe/simvastatin 10/20 mg/day, ezetimibe/simvastatin 10/40 mg/day)
Study: 28755807
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment ezetimibe/simvastatin 10/40 mg/day
Study: 28755807
Drug: Cholesterol lowering
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol lowering treatment
Study: 26887212
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy combined with diet control and physical exercise
Study: 21209230
Drug: Fosaprepitant 150
Normalized name: fosaprepitant 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 150 mg with oral dexamethasone (8 mg daily for 3 days)
Study: 21209230
Drug: Fosaprepitant 150
Normalized name: fosaprepitant 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosaprepitant 150 mg with oral midazolam (2 mg on days 1 and 4)
Study: 7839427
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) 1 mg/kg/day for 5 days
Study: 31952661
Drug: New systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New systemic and surgical treatments
Study: 21668564
Drug: Regular atrioventricular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular atrioventricular (AV) sequential pacing at 100 bpm for 30 minutes
Study: 21668564
Drug: Irregular atrioventricular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irregular atrioventricular (AV) sequential pacing at 100 bpm for 30 minutes
Study: 19332193
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical treatment (MED)
Study: 12867204
Drug: 90 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 days of free treatment coupon
Study: 12867204
Drug: Required to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Required to pay for treatment
Study: 11182626
Drug: Platelet GP
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet GP IIb/IIIa receptor antagonists (abciximab, eptifibatide, tirofiban, lamifiban)
Study: 11182626
Drug: Platelet GP
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet GP IIb/IIIa receptor antagonists
Study: 8302193
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of both drugs
Study: 3248317
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with interferon and acyclovir or descyclovir (n = 25)
Study: 3248317
Drug: Interferon treatment
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon treatment alone (n = 10)
Study: 3248317
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 18)
Study: 28604014
Drug: Videoconferencing treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconferencing treatment for depression
Study: 28604014
Drug: In-office treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office treatment for depression
Study: 26632754
Drug: Very Low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very Low Carbohydrate (LC) diet (14% energy as carbohydrate [CHO < 50 g/day], 28% protein [PRO], 58% fat [<10% saturated fat])
Study: 14577360
Drug: Ampicillin orally
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin orally 4 x 500 mg for 5 consecutive days
Study: 14577360
Drug: Ampicillin orally
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin orally 4 x 500 mg plus Gentamycin 2 x 80 mg i.m. for 3 to 5 days postoperatively
Study: 14577360
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 2 g i.v. Cefazolin intraoperatively and 24 hours following the manipulation
Study: 11319569
Drug: Controlled-release diltiazem
Normalized name: diltiazem Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release diltiazem (diltiazem CR)
Study: 11319569
Drug: Sustained-release nifedipine
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release nifedipine (nifedipine SR)
Study: 6318170
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (0.625 mg)
Study: 6318170
Drug: Depo-medroxyprogesterone acetate
Normalized name: medroxyprogesterone Injection [Depo-Provera]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo-medroxyprogesterone acetate (DMPA) (150 mg intramuscular injection)
Study: 27198039
Drug: Curanderismo treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curanderismo treatment (33 sessions over 10 months)
Study: 21097420
Drug: Continuous rocuronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous rocuronium infusion
Study: 17916229
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg q.d.)
Study: 17916229
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg b.i.d.)
Study: 12201356
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplement (two tablets daily)
Study: 10444118
Drug: 20 microg
Normalized name: Calcifediol 20 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg intranasal desmopressin
Study: 10444118
Drug: 40 microg
Normalized name: Travoprost 40 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 microg intranasal desmopressin
Study: 7774832
Drug: SRCA-guided chemotherapy
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRCA-guided chemotherapy
Study: 7028257
Drug: Cyclophosphamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (600 mg/m²), doxorubicin (40 mg/m²), and cisplatin (50 mg/m²) every 3 weeks (Group 1)
Study: 7028257
Drug: Cyclophosphamide (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (600 mg/m²), doxorubicin (40 mg/m²), and cisplatin (100 mg/m²) every 3 weeks (Group 2)
Study: 31899570
Drug: Cetirizine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (2 mg/kg)
Study: 31899570
Drug: Diphenhydramine (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (2.2 mg/kg)
Study: 11810791
Drug: Newer antihypertensive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer antihypertensive drugs (ACE inhibitors, calcium antagonists, alpha-blockers)
Study: 11810791
Drug: Older antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Older antihypertensive drugs (thiazide diuretics, beta-blockers)
Study: 7940328
Drug: Single intraarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraarticular injection of triamcinolone acetonide +/‐ cyclophosphamide
Study: 7940328
Drug: Single intraarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraarticular injection of glucocorticosteroids (methylprednisolone acetate, triamcinolone acetonide, composition with cyclophosphamide and dimethylsulfoxide)
Study: 3063286
Drug: captopril (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: captopril (75 mg/d)
Study: 3063286
Drug: canrenoate potassium
Normalized name: canrenoate potassium
DrugBank: Canrenoic acid (DB09015)
Approvals — FDA: no, EMA: no, PMDA: no
Description: canrenoate potassium (200 mg/d)
Study: 3063286
Drug: atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (100 mg/d)
Study: 31936727
Drug: CrM-HMB group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CrM-HMB group (0.04 g/kg/day of CrM plus 3 g/day of HMB)